SEC Filings
Insmed Says It Won't Build A Traditional European Sales Operation For BRINSUPRI
The drugmaker cites tight European healthcare funding and shifting US policy, and flags a pending $35.0 million AstraZeneca milestone.
SEC Filings
The drugmaker cites tight European healthcare funding and shifting US policy, and flags a pending $35.0 million AstraZeneca milestone.
SEC Filings
The HVAC maker's backlog topped $8.5 billion and it raised its 2026 sales outlook, even as a non-cash charge produced a $3.16 per-share loss.
SEC Filings
The bank's remediation bill fell to £61 million from £912 million, and it says it is on track to meet its 2026 guidance.
SEC Filings
Alphabet's quarterly report sorts $75.7 billion of data-center backstops into a new category and names a related-party venture, Crux AI.
SEC Filings
A new accounting policy puts U.S. tariff refunds against cost of goods sold, with customer shares cutting net sales.
SEC Filings
The draw on a $125.0 million facility also sets a minimum cash floor equal to 60% of outstanding loan principal.
SEC Filings
A one-time $1.23 billion Vega charge swamped profit, while Opzelura and cancer-drug sales grew and guidance rose.
SEC Filings
The heartburn-drug maker posted a second straight quarter of positive operating cash flow and held its full-year revenue forecast of $310 million to $325 million.
SEC Filings
The aerospace parts maker also added $5 billion to its buyback and floated 2027 revenue of about $11.5 billion.
SEC Filings
Garcia, 66, will draw a $100,000 salary, and Linda Rendle stays on as senior adviser through April 2, 2027.
SEC Filings
The homebuilder's cash burn widened to $267.5 million over nine months, and its $160.2 million Dallas deal is still unfinished on the books.
SEC Filings
Brent Saunders left Bausch + Lomb on October 12 with a lump-sum payment, and Bausch Health CEO Thomas Appio is now interim chief.